Bayer Healthcare LLC

Oklahoma Medical Research Foundation

Ji-Yun Kim

Xiao-Yan Zhao

Haiyan Jiang

Glenn Pierce

Jan Tebbe

Richard L Feldman

Zhuozhi Wang

Kirk McLean

Junliang Pan

James Wu

Ying Zhu

Andreas Wilmen

Christoph Freiberg

Lars Linden

Karin Regnstrom

Ursula Egner

Xinquan Wang

Subramanian Yegneswaran

Provided are humanized antibodies that selectively bind to and inhibit activated protein C without binding to or inhibiting unactivated protein C. Methods of treatment employing these antibodies are described herein.

Humanized monoclonal antibodies against activated protein c and uses thereof

Provided are optimized humanized antibodies that selectively bind to and inhibit activated protein C without binding to or inhibiting unactivated protein C. In particular, the antibodies bind to particular epitopes outside the catalytic triad of the active site of human activated protein C. Methods of treatment employing these antibodies are described herein.

Epitope of optimized humanized monoclonal antibodies against activated protein C and uses thereof

Targeted coagulation factors comprising a coagulation factor linked with at least one domain that specifically binds to a membrane protein on a blood cell is provided. The disclosed targeted coagulation factors increase the efficiency of coagulation factors and prolong their duration of action and thus, are an improvement for the treatment of hematological diseases such as hemophilia A.

Targeted coagulation factors and method of using the same

Humanized monoclonal antibodies against activated protein C and uses thereof

Growing community of inventors

Berkeley, CA, United States of America

Ji-Yun Kim